Related Experiment Videos

Differential expression of folate receptor in pituitary adenomas

Chheng-Orn Evans1, Prasad Reddy, Daniel J Brat

  • 1Department of Neurosurgery, Division of Cancer Biology, Emory University School of Medicine, Atlanta, Georgia 30322, USA.

Cancer Research
|July 23, 2003
PubMed

Insights

Folate receptor alpha (FRalpha) is overexpressed in nonfunctional pituitary adenomas, potentially aiding tumor growth. This study confirms FRalpha protein production and folate binding in these tumors.

Area of Science:

  • Endocrinology
  • Molecular Biology
  • Oncology

Background:

  • Pituitary adenomas cause significant morbidity through compression or hormone overproduction.
  • The molecular drivers of pituitary adenoma development remain largely unknown.
  • Identifying novel molecular targets is crucial for understanding tumor pathogenesis.

Purpose of the Study:

  • To investigate molecular changes in pituitary adenomas.
  • To determine the role of folate receptor alpha (FRalpha) in tumor development.
  • To assess FRalpha expression and function in different pituitary adenoma subtypes.

Main Methods:

  • cDNA microarray analysis to identify differentially expressed genes.
  • Western blotting to confirm protein expression levels.
  • Radioisotope binding assays to assess folate binding capacity.
  • Immunohistochemistry to localize FRalpha expression within tumor tissues.

Main Results:

  • FRalpha mRNA was significantly overexpressed in nonfunctional (NF) pituitary adenomas, but not in functional adenomas.
  • FRalpha protein was confirmed to be overexpressed in NF tumors.
  • Overexpressed FRalpha demonstrated specific folate binding, indicating proper folding and potential vitamin transport.
  • Immunohistochemistry revealed FRalpha expression specifically in NF adenoma cells.

Conclusions:

  • Overexpression of FRalpha mRNA in NF pituitary adenomas leads to the production of functional FRalpha protein.
  • FRalpha may play a role in mediating vitamin transport and facilitating tumor growth.
  • FRalpha represents a potential therapeutic target for nonfunctional pituitary adenomas.

Related Concept Videos